RDNT
Radnet, Inc. Health Care Services-Medical Laboratories Russell 3000
$73.49Close
$5.7BMarket cap
$51.87 – $84.4852-week range
Nov 9, 2026Next report · before the open
Highlights
Strengths
- Tight base near its pivot pullbacks 17% → 6%; 1.9% above its $72.15 pivot
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Earnings shrinking EPS −50% year on year
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
13%
1wk
up 4.5%
price change
1mo
up 6.6%
price change
12-month return
down 3%
market up 11% ·
its own down 18%
F-score
—
— Not assessed
Altman Z″
1.28
Moderate risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.2×
price / book
Earnings yield
up 1.0%
EBIT / enterprise value
Cheaper than
44%
of the market · around average
Revenue growth
up 12%
year on year
EPS growth
down 50%
latest quarter
Sales growth
up 25%
latest quarter · +3 pts
ROE
down 2%
return on equity
Free cash margin
up 15%
$298.8M FCF
D/E
0.98
long-term debt / equity
Net debt / EBITDA
1.4×
Interest cover
0.9×EBIT / interest
Trade setup
ATR%
3.2%
$2.35 a day · 2×ATR $68.78
RS
62 / 99
vs the universe
Trend
5 / 8
150-day under the 200-day, 200-day not rising, RS under 70
Relative volume
0.9×
vs 50-day average
Up/down volume
0.77
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Contractions
2
17% → 6%
Pivot
$72.15
1.9% above
Volume dry-up
0.8×
10 vs 50 sessions
Trend template · 5 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Interest is covered, but thinly Earnings before interest cover the interest bill 0.9 times, leaving little room if profits fall.
- Shareholders diluted The share count rose 4.5% over the year, from 74m to 77m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026+6% vs market2 sessions after results
Financials
- Net -1%
- Free cash 15%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.3B | $1.4B | $1.6B | $1.8B | $2.0B |
| Operating income | $35.7M | $82.6M | $46.4M | $98.7M | $104.6M | $62.0M |
| Net income | -$14.8M | $24.7M | $10.7M | $3.0M | $2.8M | -$18.6M |
| Net margin | -1% | 2% | 1% | 0% | 0% | -1% |
| Earnings per share | -$0.29 | $0.46 | $0.19 | $0.05 | $0.04 | -$0.25 |
| Free cash flow | $233.8M | $149.5M | $146.4M | $220.9M | $233.0M | $298.8M |
| Free cash margin | 22% | 11% | 10% | 14% | 13% | 15% |
| Cash | $102.0M | $134.6M | $127.8M | $342.6M | $740.0M | $767.2M |
| Long-term debt | $612.9M | $743.5M | $839.3M | $812.1M | $991.6M | $1.1B |
| Shareholders' equity | $165.7M | $228.9M | $333.0M | $630.7M | $902.3M | $1.1B |
| Shares outstanding | 51.64m | 53.55m | 57.72m | 67.96m | 74.04m | 77.40m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 26, 2026 | Material agreement · Unregistered share sale · Regulation FD ↗ |
| Aug 14, 2026 | Other events ↗ |
| Aug 10, 2026 | Results ↗ |
| Jun 10, 2026 | Material agreement · New obligation · Regulation FD ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| Jun 3, 2026 | Other events ↗ |
| May 11, 2026 | Results ↗ |
| Mar 2, 2026 | Results ↗ |
| Mar 2, 2026 | Regulation FD ↗ |
| Jan 30, 2026 | Other events ↗ |
| Jan 9, 2026 | Director or officer change · Regulation FD ↗ |
| Dec 4, 2025 | Other events ↗ |